Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Omalizumab for refractory urticaria factitia (Phase 2, randomized, double-blind, placebo-controlled)
2011-005615-87Phase 2Completed
- Sponsor
- Charité – Universitätsmedizin Berlin
- Start
- Jul 2012
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of omalizumab in Dermatographia (3 arms), sponsored by Charité – Universitätsmedizin Berlin. Primary endpoint: Change in critical friction thresholds. Started Jul 2012; status: completed.
02
Drugs
omalizumab
03
Conditions
Dermatographia
Beyond the preview
Go deeper on 2011-005615-87.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2011-005615-87.